•
Mar 30, 2024

Plexus Q2 2024 Earnings Report

Reported fiscal second quarter revenue of $967 million and non-GAAP EPS of $0.94.

Key Takeaways

Plexus reported fiscal second quarter revenue of $967 million and non-GAAP EPS of $0.94, which met the top end of guidance. The company generated free cash flow of $65 million.

Won 32 manufacturing programs during the quarter representing $255 million in annualized revenue when fully ramped into production.

Purchased $17.6 million of shares at an average price of $94.39 per share under repurchase programs.

Generated free cash flow of $65 million.

Cash cycle of 91 days, 10 days favorable to expectations and sequentially lower by four days.

Total Revenue
$967M
Previous year: $1.07B
-9.7%
EPS
$0.94
Previous year: $1.45
-35.2%
Economic Return
1.7%
Previous year: 4.8%
-64.6%
Cash Cycle
91
Gross Profit
$88.1M
Previous year: $103M
-14.5%
Cash and Equivalents
$265M
Previous year: $270M
-1.7%
Free Cash Flow
$64.9M
Previous year: $79.6M
-18.5%
Total Assets
$3.28B
Previous year: $3.38B
-3.1%

Plexus

Plexus

Plexus Revenue by Segment

Plexus Revenue by Geographic Location

Forward Guidance

Plexus is guiding fiscal third quarter revenue of $960 million to $1.00 billion, non-GAAP operating margin of 5.2% to 5.6% and non-GAAP EPS of $1.22 to $1.37.

Positive Outlook

  • Revenue growth is in the early stages of inflecting higher.
  • Benefiting from robust demand within the Aerospace and Defense market sector.
  • Gradually recovering semiconductor capital equipment demand.
  • New program ramps are mitigating inventory correction headwinds in Healthcare/Lifesciences.
  • New program ramps are mitigating inventory correction headwinds in Industrial market sectors.

Challenges Ahead

  • Non-GAAP operating margin excludes approximately $6.5 million of restructuring charges associated with realigning manufacturing capabilities to best support long-term customer needs
  • Non-GAAP operating margin excludes approximately $6.2 million of stock-based compensation expense.
  • Inventory correction headwinds in Healthcare/Lifesciences market sectors.
  • Inventory correction headwinds in Industrial market sectors.
  • Restructuring charges associated with realigning manufacturing capabilities.

Revenue & Expenses

Visualization of income flow from segment revenue to net income